Maximilian Steinhardt

15PUBLICATIONS
112CO-AUTHORS
Predictive and prognostic markersAutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursReceptors and membrane biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 25, 2026
Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

|Jun 18, 2026
Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases.

|Jun 08, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

|Apr 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

|Feb 13, 2026
Clinical Scores to Predict Toxicities and Outcomes in Patients with Multiple Myeloma Undergoing Bispecific T-cell Engager Therapy.

Jan H Frenking, Christine Riedhammer, Thomas Hielscher

|Feb 04, 2026
Single-molecule localization microscopy reveals the molecular organization of endogenous membrane receptors.

Patrick Eiring, Maximilian J Steinhardt, Nele Bauer

Pageof 3

Frequent Collaborators

9 joint publications

Martin Kortüm

7 joint publications

Hermann Einsele

5 joint publications

Leo Rasche

3 joint publications

Eli Muchtar